Recent news reports indicate the Tricon Timber‘s St. Regis, Montana stud mill has been purchased by Idaho Forest Group, one of the largest lumber producers in the U.S. Idaho Forest Group is based in Coeur d’Alene and is a family-owned wood products company, founded in 1981, that grows, harvests, manufactures and distributes wood products. The deal is scheduled to become …
Steel Marking – U.S. Steel Producers Combatting Declining Prices
During the second week of November, the U.S. cold rolled coil (CRC) prices weakened, according to Platts Steel Market Daily global market reports. Prices in the U.S. steel market have been range-bound this year according to reports, although prices, a key driver in earnings for steel companies, have been volatile in recent years. Recent news reports say that the second …
Pharma News – CVS Taking Steps To Counter Perceived Amazon Threat
With pharmacies not certain of whether or not Amazon will expand into the prescription drug arena, some are taking steps in an effort to preserve their business and compete in the event the e-tail giant does venture into this market. In recent pharma news, CVS Health has announced that in 2018 it will begin offering same-day delivery of prescription drugs …
Evidence Of Amazon’s Intention To Get Into Pharmaceutical Industry
More and more, it’s looking as though e-commerce giant, Amazon, has strong intentions of getting into the pharmaceutical drug industry as it continues to obtain approval for wholesale distributorship of pharmaceuticals in a mounting number of states. How will this impact the pharmaceutical industry? According to recent reports, Amazon would need a pharmacy license to sell medical devices or prescription …
Pharma Coding – Bristol-Myers Squibb Acquires IFM Therapeutics
Recent news reports reveal that BMS and IFM Therapeutics have signed an agreement in which Bristol-Myers Squibb will acquire full rights to IFM’s NLRP3 and STING agonist programs in an effort to target innate immunity pathways that could potentially assist the body’s natural defenses in recognizing tumors and attacking them, expanding and complementing Bristol-Myers Squibb’s immuno-oncology portfolio. Reports claim BMS …